Oxidative stress-related mechanisms affecting response to aspirin in diabetes mellitus

Free Radical Biology and Medicine

Volumn 80, Issue , 2015, Pages 101-110

  Santilli, Francesca ^a   Lapenna, Domenico ^a   La Barba, Sara ^a   Davì, Giovanni ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Aspirin responsiveness; Cardiovascular disease; Diabetes mellitus; Free radicals; Lipid peroxidation; Oxidative stress

Indexed keywords

8 ISOPROSTANE; ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; ALDEHYDE REDUCTASE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; HEME OXYGENASE; HYDROPEROXIDE; HYDROXYL RADICAL; IRON; ISOPROSTANE DERIVATIVE; LIPID HYDROPEROXIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXYNITRITE; PHOSPHOLIPASE A2; PROSTAGLANDIN G2; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; THROMBOXANE A2; THROMBOXANE RECEPTOR; ANTITHROMBOCYTIC AGENT; GLUCOSE; LIPID PEROXIDE; PEROXYNITROUS ACID;

ACETYLATION; ARTICLE; BODY MASS; DYSLIPIDEMIA; ENZYME ACTIVATION; ENZYME ACTIVE SITE; GENE EXPRESSION; GLYCATION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; LIPID PEROXIDATION; MEGAKARYOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PLATELET REACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE VOLUME; THROMBOCYTOPOIESIS; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLYCOSYLATION; METABOLISM; PATHOLOGY; THROMBOSIS;

ALDEHYDE REDUCTASE; ASPIRIN; BLOOD PLATELETS; DIABETES MELLITUS, TYPE 2; F2-ISOPROSTANES; GLUCOSE; GLYCOSYLATION; HUMANS; LIPID PEROXIDES; NITRIC OXIDE; OXIDATIVE STRESS; PEROXYNITROUS ACID; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; THROMBOSIS; THROMBOXANE A2;

EID: 84921504941     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2014.12.010     Document Type: Review

References (82)

1. C. Patrono Aspirin as an antiplatelet drug N. Engl. J. Med. 330 1994 1287 1294
2. F. Santilli, B. Rocca, R. De Cristofaro, S. Lattanzio, L. Pietrangelo, A. Habib, C. Pettinella, A. Recchiuti, E. Ferrante, G. Ciabattoni, G. Davì, and C. Patrono Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin resistance J. Am. Coll. Cardiol. 53 2009 667 677
3. G. Davi, and C. Patrono Platelet activation and atherothrombosis N. Engl. J. Med. 357 2007 2482 2494
4. F. Santilli, M. Romano, A. Recchiuti, A. Dragani, A. Falco, G. Lessiani, F. Fioritoni, S. Lattanzio, D. Mattoscio, R. De Cristofaro, B. Rocca, and G. Davi Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients Blood 112 2008 1085 1090
5. S Pascale, G. Petrucci, A. Dragani, A. Habib, F. Zaccardi, F. Pagliaccia, D. Pocaterra, E. Ragazzoni, G. Rolandi, B. Rocca, and C. Patrono Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target Blood 119 2012 3595 3603
6. C. Patrono, and B. Rocca Aspirin: promise and resistance in the new millennium Arterioscler. Thromb. Vasc. Biol. 28 2008 s25 32
7. A.L. Frelinger, Y. Li, M.D. Linden, M.R. Barnard, M.L. Fox, D.J. Christie, M.I. Furman, and A.D. Michelson Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization Circulation 120 2009 2586 2596
8. A.L. Frelinger, Y. Li, M.D. Linden, I. Tarnow, M.R. Barnard, M.L. Fox, and A.D. Michelson Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests J. Thromb. Haemostasis 6 2008 2035 2044
9. M. Pignone, M.J. Alberts, J.A. Colwell, M. Cushman, S.E. Inzucchi, D. Mukherjee, R.S. Rosenson, C.D. Williams, P.W. Wilson, and M.S. Kirkman Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation Circulation 121 2010 2694 2701
10. C. Baigent, L. Blackwell, R. Collins, J. Emberson, J. Godwin, R. Peto, J. Buring, C. Hennekens, P. Kearney, T. Meade, C. Patrono, M.C. Roncaglioni, and A. Zanchetti Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 2009 1849 1860
11. N. Vazzana, F. Santilli, S. Sestili, C. Cuccurullo, and G. Davi Determinants of increased cardiovascular disease in obesity and metabolic syndrome Curr. Med. Chem. 18 2011 5267 5280
12. F. Giacco, and M. Brownlee Oxidative stress and diabetic complications Circ. Res. 107 2010 1058 1070
13. J. Cassuto, H. Dou, I. Czikora, A. Szabo, V.S. Patel, V. Kamath, E. Belin de Chantemele, A. Feher, M.J. Romero, and Z. Bagi Peroxynitrite disrupts endothelial caveolae leading to eNOS uncoupling and diminished flow-mediated dilation in coronary arterioles of diabetic patients Diabetes 63 2014 1381 1393
14. F. Cosentino, M. Eto, P. De Paolis, B. van der Loo, M. Bachschmid, V. Ullrich, A. Kouroedov, C. Delli Gatti, H. Joch, M. Volpe, and T.F. Luscher High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species Circulation 107 2003 1017 1023
15. T.V. Fiorentino, A. Prioletta, P. Zuo, and F. Folli Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases Curr. Pharm. Des 19 2013 5695 5703
16. G. Davi, A. Falco, and C. Patrono Lipid peroxidation in diabetes mellitus Antioxid. Redox Signaling 7 2005 256 268
17. G. Anfossi, I. Russo, and M. Trovati Resistance to aspirin and thienopyridines in diabetes mellitus and metabolic syndrome Curr. Vasc. Pharmacol. 6 2008 313 328
18. S.K. Karmohapatra, K. Chakraborty, N.N. Kahn, and A.K. Sinha The role of nitric oxide in aspirin induced thrombolysis in vitro and the purification of aspirin activated nitric oxide synthase from human blood platelets Am. J. Hematol. 82 2007 986 995
19. P.C. Williams, M.J. Coffey, B. Coles, S. Sanchez, J.D. Morrow, J.R. Cockcroft, M.J. Lewis, and V.B. O'Donnell In vivo aspirin supplementation inhibits nitric oxide consumption by human platelets Blood 106 2005 2737 2743
20. I. Russo, C. Barale, L. Mattiello, G. Doronzo, A. Pagliarino, F. Cavalot, M. Trovati, and G. Anfossi High glucose inhibits the aspirin-induced activation of the nitric oxide/cGMP/cGMP-dependent protein kinase pathway and does not affect the aspirin-induced inhibition of thromboxane synthesis in human platelets Diabetes 61 2012 2913 2921
21. C. Watala, M. Boncler, and P. Gresner Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus Pharmacol. Rep. 57 Suppl 2005 42 58
22. C. Watala, J. Pluta, J. Golanski, M. Rozalski, M. Czyz, Z. Trojanowski, and J. Drzewoski Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin J. Mol. Med. (Berlin) 83 2005 148 158
23. C. Watala, O. Ulicna, J. Golanski, M. Nocun, I. Waczulikova, L. Markuszewski, and J. Drzewoski High glucose contributes to aspirin insensitivity in streptozotocin-diabetic rats: a multiparametric aggregation study Blood Coagulation Fibrinolysis 17 2006 113 124
24. B. Rocca, F. Santilli, D. Pitocco, L. Mucci, G. Petrucci, E. Vitacolonna, S. Lattanzio, D. Mattoscio, F. Zaccardi, R. Liani, N. Vazzana, A. Del Ponte, E. Ferrante, F. Martini, C. Cardillo, R. Morosetti, M. Mirabella, G. Ghirlanda, G. Davì, and C. Patrono The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes J. Thromb. Haemostasis 10 2012 1220 1230
25. J.P. Smith, E.V. Haddad, M.B. Taylor, D. Oram, D. Blakemore, Q. Chen, O. Boutaud, and J.A. Oates Suboptimal inhibition of platelet cyclooxygenase-1 by aspirin in metabolic syndrome Hypertension 59 2012 719 725
26. J. Nourooz-Zadeh, J. Tajaddini-Sarmadi, S. McCarthy, D.J. Betteridge, and S.P. Wolff Elevated levels of authentic plasma hydroperoxides in NIDDM Diabetes 44 1995 1054 1058
27. I. Antonipillai, J. Nadler, E.J. Vu, S. Bughi, R. Natarajan, and R. Horton A 12-lipoxygenase product, 12-hydroxyeicosatetraenoic acid, is increased in diabetics with incipient and early renal disease J. Clin. Endocrinol. Metab. 81 1996 1940 1945
28. T.J. Berg, J. Nourooz-Zadeh, S.P. Wolff, H.J. Tritschler, H.J. Bangstad, and K.F. Hanssen Hydroperoxides in plasma are reduced by intensified insulin treatment: a randomized controlled study of IDDM patients with microalbuminuria Diabetes Care 21 1998 1295 1300
29. C. Calzada, E. Vericel, and M. Lagarde Low concentrations of lipid hydroperoxides prime human platelet aggregation specifically via cyclo-oxygenase activation Biochem. J. 325 1997 495 500
30. L. Coulon, C. Calzada, P. Moulin, E. Vericel, and M. Lagarde Activation of p38 mitogen-activated protein kinase/cytosolic phospholipase A2 cascade in hydroperoxide-stressed platelets Free Radic. Biol. Med. 35 2003 616 625
31. C.A. Rouzer, and L.J. Marnett Cyclooxygenases: structural and functional insights J. Lipid Res 50 Suppl 2009 S29 34
32. M. Bala, C. Chin, A.T. Logan, T. Amin, L.J. Marnett, O. Boutaud, and J.A. Oates Acetylation of prostaglandin H2 synthases by aspirin is inhibited by redox cycling of the peroxidase Biochem. Pharmacol. 75 2008 1472 1481
33. R.M. Botting Inhibitors of cyclooxygenases: mechanisms, selectivity and uses J. Physiol. Pharmacol. 57 Suppl. 5 2006 113 124
34. R.J. Kulmacz Regulation of cyclooxygenase catalysis by hydroperoxides Biochem. Biophys. Res. Commun. 338 2005 25 33
35. G.P. Hochgesang, S.W. Rowlinson, and L. Marnett Tyrosine-385 is critical for acetylation of cyclooxygenase-2 by aspirin J. Am. Chem. Soc. 122 2000 6514 6515
36. M. Spite, and C.N. Serhan Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins Circ. Res. 107 2010 1170 1184
37. F. Ursini, A. Zamburlini, G. Cazzolato, M. Maiorino, G.B. Bon, and A. Sevanian Postprandial plasma lipid hydroperoxides: a possible link between diet and atherosclerosis Free Radic. Biol. Med. 25 1998 250 252
38. L.M. Landino, B.C. Crews, M.D. Timmons, J.D. Morrow, and L.J. Marnett Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis Proc. Natl. Acad. Sci. USA 93 1996 15069 15074
39. L.J. Marnett Cyclooxygenase mechanisms Curr. Opin. Chem. Biol. 4 2000 545 552
40. P. Pacher, and C. Szabo Role of peroxynitrite in the pathogenesis of cardiovascular complications of diabetes Curr. Opin. Pharmacol. 6 2006 136 141
41. G. Davi, F. Chiarelli, F. Santilli, M. Pomilio, S. Vigneri, A. Falco, S. Basili, G. Ciabattoni, and C. Patrono Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration Circulation 107 2003 3199 3203
42. R.P. Robertson, J. Harmon, P.O. Tran, and V. Poitout Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes Diabetes 53 Suppl. 1 2004 S119 124
43. F. Chiarelli, F. Santilli, G. Sabatino, A. Blasetti, S. Tumini, F. Cipollone, A. Mezzetti, and A. Verrotti Effects of vitamin E supplementation on intracellular antioxidant enzyme production in adolescents with type 1 diabetes and early microangiopathy Pediatr. Res. 56 2004 720 725
44. C. Patrono, A. Falco, and G. Davi Isoprostane formation and inhibition in atherothrombosis Curr. Opin. Pharmacol. 5 2005 198 203
45. G. Davi, and A. Falco Oxidant stress, inflammation and atherogenesis Lupus 14 2005 760 764
46. F. Santilli, L. Mucci, and G. Davi TP receptor activation and inhibition in atherothrombosis: the paradigm of diabetes mellitus Intern. Emerg. Med 6 2011 203 212
47. V. Capra, M. Back, D.J. Angiolillo, M. Cattaneo, and K.S. Sakariassen Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation J. Thromb. Haemostasis 12 2014 126 137
48. P. Pignatelli, R. Carnevale, S. Di Santo, S. Bartimoccia, V. Sanguigni, L. Lenti, A. Finocchi, L. Mendolicchio, A.R. Soresina, A. Plebani, and F. Violi Inherited human gp91phox deficiency is associated with impaired isoprostane formation and platelet dysfunction Arterioscler. Thromb. Vasc. Biol. 31 2011 423 434
49. F. Santilli, G. Davi, A. Consoli, F. Cipollone, A. Mezzetti, A. Falco, T. Taraborelli, E. Devangelio, G. Ciabattoni, S. Basili, and C. Patrono Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus J. Am. Coll. Cardiol. 47 2006 391 397
50. F. Santilli, G. Davi, S. Basili, S. Lattanzio, A. Cavoni, G. Guizzardi, L. De Feudis, G Traisci, C. Pettinella, L. Paloscia, P. Minuz, A. Meneguzzi, G. Ciabattoni, and C. Patrono Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment J. Thromb. Haemostasis 8 2010 914 922
51. J. Bauer, A. Ripperger, S. Frantz, S. Ergün, E. Schwedhelm, and R.A. Benndorf Pathophysiology of isoprostanes in the cardiovascular system: implications of isoprostane-mediated thromboxane A2 receptor activation Br. J. Pharmacol. 171 2014 3115 3131
52. E. Schwedhelm, A Bierend, R. Maas, R. Trinks, G.D. Kom, D. Tsikas, and R.H. Boger Redox-generated isoprostanes are associated with residual platelet activity in aspirin-treated patients with stable coronary heart disease J. Thromb. Haemostasis 8 2010 2662 2670
53. R. Kranzhofer, and J. Ruef Aspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the PlA(1/2) polymorphism Platelets 17 2006 163 169
54. P.R. Ames, J.R. Batuca, I.J. Muncy, I.G. De La Torre, S. Pascoe-Gonzales, K. Guyer, E. Matsuura, and L.R. Lopez Aspirin insensitive thromboxane generation is associated with oxidative stress in type 2 diabetes mellitus Thromb. Res. 30 2012 350 354
55. P.J. Mateos-Caceres, C. Macaya, L. Azcona, J. Modrego, E. Mahillo, E. Bernardo, A. Fernandez-Ortiz, and A.J. Lopez-Farre Different expression of proteins in platelets from aspirin-resistant and aspirin-sensitive patients Thromb. Haemostasis 103 2010 160 170
56. M. Lordkipanidzé, J. Turgeon, E. Schampaert, D.A. Palisaitis, and C. Pharand Platelet count, not oxidative stress, may contribute to inadequate platelet inhibition by aspirin Int. J. Cardiol. 143 2010 43 50
57. B. Rocca, F. Santilli, D. Pitocco, L. Mucci, G Petrucci, E. Vitacolonna, S. Lattanzio, D. Mattoscio, F. Zaccardi, R. Liani, N. Vazzana, A. Del Ponte, E. Ferrante, F. Martini, G. Ghirlanda, G. Davì, and C. Patrono Variability in the recovery rate of platelet cyclooxygenase activity during chronic therapy with low-dose aspirin in type 2 diabetes Circulation 122 2010 530 ([Abstract 12233])
58. A. Undas, Z. Siudak, R. Topór-Mądry, M. Les̈niak, and W. Tracz Simvastatin administration reduces thromboxane production in subjects taking aspirin: links between aspirin resistance and thrombin generation Int. J. Cardiol. 154 2012 59 64
59. R. Cangemi, P. Pignatelli, R. Carnevale, C. Nigro, M. Proietti, F. Angelico, D. Lauro, S. Basili, and F. Violi Platelet isoprostane overproduction in diabetic patients treated with aspirin Diabetes 61 2012 1626 1632
60. P. Pignatelli, R. Carnevale, D. Pastori, R. Cangemi, L. Napoleone, S. Bartimoccia, C. Nocella, S. Basili, and F. Violi Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of NOX2 Circulation 126 2012 92 103
61. W.H. Tang, J. Stitham, S. Gleim, C. Di Febbo, E. Porreca, C. Fava, S. Tacconelli, M. Capone, V. Evangelista, G. Levantesi, L. Wen, K. Martin, P. Minuz, J. Rade, P. Patrignani, and J. Hwa Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane J. Clin. Invest. 121 2011 4462 4476
62. J.J. O'Brien, C.J. Baglole, T.M. Garcia-Bates, N. Blumberg, C.W. Francis, and R.P. Phipps 15-Deoxy-delta12,14 prostaglandin J2-induced heme oxygenase-1 in megakaryocytes regulates thrombopoiesis J. Thromb. Haemostasis 7 2009 182 189
63. J.M. Fernández-Real, A. López-Bermejo, and W. Ricart Cross-talk between iron metabolism and diabetes Diabetes 51 2002 2348 2354
64. S.N. Rajpathak, J.P. Crandall, J. Wylie-Rosett, G.C. Kabat, T.E. Rohan, and F.B. Hu The role of iron in type 2 diabetes in humans Biochim. Biophys. Acta 1790 2009 671 681
65. D.H. Lee, D.Y. Liu, D.R. Jacobs Jr, H.R. Shin, K. Song, I.K. Lee, B. Kim, and R.C. Hider Common presence of non-transferrin-bound iron among patients with type 2 diabetes Diabetes Care 29 2006 1090 1095
66. K.B. Schwarz, B.J. Arey, K. Tolman, and S. Mahanty Iron chelation as a possible mechanism for aspirin-induced malondialdehyde production by mouse liver microsomes and mitochondria J. Clin. Invest. 81 1988 165 170
67. N.R. Campbell, and B.B. Hasinoff Iron supplements: a common cause of drug interactions Br. J. Clin. Pharmacol. 31 1991 251 255
68. D. Jay, E.G. Jay, and M.A. Medina Superoxide dismutase activity of the salicylate-iron complex Arch. Med. Res. 30 1999 93 96
69. D. Lapenna, G. Ciofani, S.D. Pierdomenico, M. Neri, C. Cuccurullo, M.A. Giamberardino, and F. Cuccurullo Inhibitory activity of salicylic acid on lipoxygenase-dependent lipid peroxidation Biochim. Biophys. Acta 1790 2009 25 30
70. Y. Fujita, I. Mori, K. Fujita, S. Kitano, and T. Tanaka A color reaction of 1,2-diphenols based on colored complex formation with phenylfluorone and iron(III) and its application to the assay of catecholamines in pharmaceutical preparations Chem. Pharm. Bull. (Tokyo) 33 1985 5385 5392
71. 2-receptor antagonists are scavengers of oxygen radicals Eur. J. Clin. Invest. 24 1994 476 481
72. D. Lapenna, S. De Gioia, G. Ciofani, D. Festi, and F. Cuccurullo Antioxidant properties of omeprazole FEBS Lett. 382 1996 189 192
73. 2) challenge Pediatr. Res. 12 1978 927 931
74. M. Tien, L. Morehouse, J.R. Bucher, and S.D. Aust The multiple effects of ethylenediaminetetraacetate in several model lipid peroxidation systems Arch. Biochem. Biophys. 218 1982 450 458
75. D. Praticò, M. Pasin, O.P. Barry, A. Ghiselli, G. Sabatino, L. Iuliano, G.A. FitzGerald, and F. Violi Iron-dependent human platelet activation and hydroxyl radical formation: involvement of protein kinase C Circulation 99 1999 3118 3124
76. R. Le Lacheur, and W. Glaze Reactions of ozone and hydroxyl radicals with serine Environ. Sci. Technol. 30 1996 1072 1080
77. Z. Maskos, J.D. Rush, and W.H. Koppenol The hydroxylation of phenylalanine and tyrosine: a comparison with salicylate and tryptophan Arch. Biochem. Biophys. 296 1992 521 529
78. T. Ito, S. Morimoto, S. Fujita, and S. Nashimoto Radical intermediates generated in the reaction of L-arginine with hydroxyl radical and sulfate radical anion: a pulse radiolysis study Radiat. Phys. Chem. 78 2008 256 260
79. 2 production) by ascorbic acid and glucose in the presence of aminotriazole: role of transition metals and relevance to diabetes Biochem. J. 303 1994 935 939
80. G. De Berardis, M. Sacco, V. Evangelista, A. Filippi, C.B. Giorda, G Tognoni, U. Valentini, and A. Nicolucci Aspirin and simvastatin combination for cardiovascular events prevention trial in diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins Trials 8 2007 21
81. Q. Huang, A. Sparatore, P. Del Soldato, L. Wu, and K. Desai Hydrogen sulfide releasing aspirin, ACS14, attenuates high glucose-induced increased methylglyoxal and oxidative stress in cultured vascular smooth muscle cells. PLoS One 9 2014 e97315
82. P Patrignani, S. Tacconelli, E. Piazuelo, L. Di Francesco, M. Dovizio, C. Sostres, E. Marcantoni, P. Guillem-Llobat, P. Del Boccio, M. Zucchelli, C. Patrono, and A. Lanas Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action J. Thromb. Haemostasis 12 2014 1320 1330